 After reviewing the FDAs information requests and considering all other options, DBV Technologies NASDAQ: DBVT has decided not to pursue the sequential approach to develop Viaskin Peanut allergen uptaketransport study before STAMP. DBV estimates that heeding to the FDAs newly proposed sequential approach would require at least five rounds of exchanges requiring FDA alignment before initiating STAMP, a 6-month safety, and adhesion study. 